Skip to content

Ketamine: all studies

Page 118 of 449: studies 1,171 to 1,180 of 4,483, newest first. Back to the ketamine overview

Research

Ketamine and chronic treatment-resistant depression: real-world practice and after relapse.

BMC Psychiatry October 28, 2024 Sumaya Jobnah, Youssef Latifeh, Dina Al Kabani et al. 2 citations

Chronic treatment-resistant depression (TRD) poses a major challenge for clinicians. Ketamine has shown a rapid but short-lived antidepressant effect in several studies involving TRD patients with different demographic and clinical profiles. Our study aimed to assess the antidepressant effect of serial infusion sessions of ketamine in patients with chronic TRD and evaluate the severity of...

Advancing ketamine in the treatment hierarchy for refractory depression.

The British Journal of Psychiatry October 25, 2024 Kabir Nigam, Franklin King, Fernando Espí Forcén 2 citations

Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strategies for refractory depression. This, combined with data on psychiatric treatment outcome mediators, suggests that earlier intervention with ketamine could improve outcomes for patients suffering from refractory depression.

DOI: 10.1192/bjp.2024.217 (opens in new tab) Full text (opens in new tab) Antidepressants Depressive disorders General adult psychiatry Psychopharmacology +6

Local activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes.

medRxiv October 21, 2024 Pascal Grumbach, Jan Kasper, Joerg F. Hipp et al. 1 citation preprint

Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with altered resting-state brain function. An increased excitation-inhibition (E/I) ratio is discussed as a potential pathomechanism but in-vivo evidence of disturbed neurotransmission underlying these functional alterations remains scarce. We compared rs-fMRI local activity (LCOR) between ASD (N=405, N=395) and...

DOI: 10.1101/2024.10.20.24315801 (opens in new tab) Full text (opens in new tab) Autism spectrum disorders Brain chemistry Neurotransmitters Ketamine research

Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors.

Molecular Pharmacology October 17, 2024 Ivone Gomes, Achla Gupta, Elyssa B Margolis et al. 21 citations

Ketamine is a glutamate receptor antagonist that was developed over 50 years ago as an anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics and fast-acting antidepressants, presumably through targets other than glutamate receptors. We tested ketamine and its metabolites for activity as allosteric modulators of opioid receptors expressed as recombinant receptors...

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...

An evaluation of the efficacy and side effects of a single dose of ketamine in major depressive disorder.

Postgraduate Medical Journal October 14, 2024 Betül Uyar, Mehmet Güneş 1 citation

This study aims to provide a comprehensive overview of the antidepressant and antisuicidal efficacy of ketamine in patients with unipolar depression, with a focus on the clinical evidence and safety profile. In our study, the data of 120 major depressive disorder patients who received single-dose ketamine infusion therapy were evaluated retrospectively, with Montgomery-Asberg Depression Rating...

DOI: 10.1093/postmj/qgae142 (opens in new tab) Full text (opens in new tab) Single dose Suicide Depression treatment Ketamine therapy +3

Functional activity and connectivity signatures of ketamine and lamotrigine during negative emotional processing: a double-blind randomized controlled fMRI study.

Translational Psychiatry October 14, 2024 Marvin S Meiering, David Weigner, Matti Gärtner et al. 4 citations

Ketamine is a highly effective antidepressant (AD) that targets the glutamatergic system and exerts profound effects on brain circuits during negative emotional processing. Interestingly, the effects of ketamine on brain measures are sensitive to modulation by pretreatment with lamotrigine, which inhibits glutamate release. Examining the antagonistic effects of ketamine and lamotrigine on...

Long-Term Effects of Single and Repeated Ketamine Infusions on Treatment-Resistant Depression: A Retrospective Chart Review Study

Psychoactives October 12, 2024 Sofia Sakopoulos, Lisa D. Hinz 4 citations

Treatment-resistant depression (TRD) is a substantial public health burden with limited treatment options. Recent evidence suggests that single and repeated-dose ketamine infusions have rapid and significant antidepressant effects on individuals with TRD. Few studies have compared single or repeated (6) ketamine infusions past 14 days post-treatment. This retrospective chart review study...

Mental Health Facilities With Ketamine Infusion Therapy in the United States in 2020: Co-Location of Dual Diagnosis Mental Health and Substance Use Disorder Treatment

Carolina Digital Repository October 9, 2024 Orrin D. Ware

Ketamine is an anesthetic that has been identified as an effective therapy for depressive disorders and related symptoms. Some studies have identified ketamine as having the potential to reduce substance use among individuals with a substance use disorder (SUD)-alongside psychotherapy. Further, SUDs often co-occur with depressive disorders. Using the National Mental Health Services Survey 2020,...

DOI: 10.17615/rd8y-nq91 (opens in new tab) Ketamine Mental health Dual diagnosis Dual grammatical number +1

Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.

European Archives of Psychiatry and Clinical Neuroscience October 9, 2024 Jiafeng Li, Ling Ma, Huan Sun et al. 5 citations

The current systematic review and meta-analysis examined the effect of racemic ketamine or esketamine on suicidal ideation in individuals with uni- or bipolar depression. We searched the MEDLINE, Embase, Central, PsycINFO, and Web of Science databases to identify randomized controlled trials that examined the effect of racemic ketamine or esketamine monotherapy on suicidal ideation (SI) in...